Loading stock…

Arcutis Biotherapeutics, Inc. (ARQT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Arcutis Biotherapeutics, Inc.

ARQTMarket cap $3.01BPrice $23.9

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops prescription skin treatments for chronic conditions like psoriasis and eczema, targeting diseases that affect over 7.5 million Americans. Its lead drug Zoryve is carving out share in a dermatology market long dominated by decades-old steroid creams.

In Bastion Portfolios?

52W Return+15%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+367%10

Revenue Forecast

Rev CAGR (1y)+43%10

Rev CAGR (3y)+30%10

Rev CAGR (5y)+24%10

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+243%10

EPS Growth Y+3+67%10

Quality

Margins

EBIT Margin7%4

Net Income Margin6%4

Free Cash Flow Margin8%5

Debt

Net Debt/EBITDA-3.310

Efficiency

ROE16%7

ROA7%7

Earnings Stability22

GEAR+AVERAGE67

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)332

P/E Ratio (Forward 3y)98

P/BV13.61

EV Multiples

EV/EBITDA Fwd301

EV/EBIT Fwd461

Yield

Free Cash Flow Yield1.3%3

Dividend Yieldna–

Momentum

Short term

1 month return+0%8

3 month return-14%3

YTD return-18%2

Mid term

Price vs 52wHigh75%4

1 year return+16%7

Long term

3 year return+410%10

5 year return+4%4

Risk Shield

Price Risk

Beta0.76

Volatility55%3

Free Cash Flow

Free Cash Flow Margin8%5

Free Cash Flow Yield1.3%3

Quality

ROCE12%6

Earnings Stability22

Net Debt/EBITDA-3.310

02Growth

Is it actually growing, and how fast?

ARQTArcutis Biotherapeutics

Revenue FY25$376M

GROWTH RATING↗

VERY STRONG98 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+367%10

Revenue, next 1Y+43%10

Revenue, next 3Y, CAGR+30%10

Revenue, next 5Y, CAGR+24%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+243%10

EPS growth, FY28E+67%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 98% of companies worldwide.

Revenue grew 367%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 30%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 24%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 67%/yr vs revenue 30%/yr), so margins should widen.

WATCH

Revenue grew 367%/yr over the last 3 years; forecasts see it cooling to 30%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE53 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return-14%3

YTD return-18%2

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+16%7

3-year return+410%10

5-year return+4%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +410% over three years and +3.7% over five, ahead of 60% of the market.

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

It's up 16% over the past year, but 25% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

The stock is underperforming over three months (-14%) and so far this year (-18%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the stock is underperforming over three months and so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Arcutis Biotherapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ARQTArcutis Biotherapeutics

Revenue FY25$376M

GROWTH RATING↗

VERY STRONG98 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+367%10

Revenue, next 1Y+43%10

Revenue, next 3Y, CAGR+30%10

Revenue, next 5Y, CAGR+24%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+243%10

EPS growth, FY28E+67%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 98% of companies worldwide.

Revenue grew 367%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 30%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 24%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 67%/yr vs revenue 30%/yr), so margins should widen.

WATCH

Revenue grew 367%/yr over the last 3 years; forecasts see it cooling to 30%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE53 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return-14%3

YTD return-18%2

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+16%7

3-year return+410%10

5-year return+4%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +410% over three years and +3.7% over five, ahead of 60% of the market.

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

It's up 16% over the past year, but 25% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

The stock is underperforming over three months (-14%) and so far this year (-18%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Arcutis Biotherapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community